Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment

What Was Tested

Researchers studied Vasopressin in this clinical trial publication.

15 ADPKD (eGFR<60) patients and 15 age-, sex- and eGFR-matched controls with IgA nephropathy (IgAN), underwent a water deprivation test to determine maximal urine concentrating capacity.

Why It Was Studied

Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients have an impaired urine concentrating capacity.

The researchers hypothesized that ADPKD patients have a more severely impaired urine concentrating capacity in comparison to other patients with chronic kidney disease at a similar level of kidney function, with consequently an enhanced AVP response to water deprivation with higher circulating AVP concentrations.

Who Took Part

The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.

In ADPKD patients, height adjusted total kidney volume (hTKV) was measured by MRI.

How the Study Was Run

Plasma and urine osmolality, urine aquaporin-2 (AQP2) and plasma AVP and copeptin (a surrogate marker for AVP) were measured at baseline and after water deprivation (average 16 hours).

What Was Measured

The researchers hypothesized that ADPKD patients have a more severely impaired urine concentrating capacity in comparison to other patients with chronic kidney disease at a similar level of kidney function, with consequently an enhanced AVP response to water deprivation with higher circulating AVP concentrations.

The subject headings attached to it are Aquaporin 2, Glomerulonephritis, IGA, Glycopeptides, Kidney Concentrating Ability, Magnetic Resonance Imaging, Polycystic Kidney, Autosomal Dominant and Vasopressins.

What This Means in Plain Language

This is a clinical trial of Vasopressin.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (PloS one), a journal based in United States.

More context: the Vasopressin compound page, all human trials.